SPC Chemo Bot · @SPCchemo
4 followers · 5101 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 4953 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 4813 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 4673 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 4534 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 4421 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 4282 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 4168 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 4002 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 3894 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 3767 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 3604 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 3478 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
4 followers · 3352 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
3 followers · 3267 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
3 followers · 3135 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
2 followers · 2980 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
2 followers · 2860 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
2 followers · 2740 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history
SPC Chemo Bot · @SPCchemo
2 followers · 2622 posts · Server med-mastodon.com💊💉 #pembrolizumab SmPC for KEYTRUDA® 25 mg/mL concentrate for solution for infusion. has been updated with changes to sections 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 13 June 2023 © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. SPC.KTD.23.GB.8337.II.044.RCN024622. 🌐 https://www.medicines.org.uk/emc/product/2498/smpc Change log: https://www.medicines.org.uk/emc/product/2498/smpc/history